Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HTR2A | P28223 | 9/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1351804 | 0.86 | KDM4E (0.62) | ALDH1A1HTTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL13948896 | 0.85 | ALDH1A1 (0.70) | ALDH1A1HTTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL13948897 | 0.85 | MMP13 (0.56) | ALDH1A1HTR2ASLC6A4KCNH2HTT | |
| SCHEMBL13973310 | 0.84 | ALDH1A1 (0.57) | ALDH1A1HTTSMN1; SMN2KDM4ELMNA | |
| SCHEMBL13958879 | 0.83 | ALDH1A1 (0.51) | ALDH1A1HTTSMN1; SMN2KDM4ELMNA | |
| SCHEMBL8241107 | 0.81 | ALDH1A1 (0.62) | ALDH1A1HTTSMN1; SMN2KDM4ELMNA | |
| SCHEMBL17227470 | 0.81 | KDM4E (0.50) | ALDH1A1HTTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL8985544 | 0.81 | MEN1 (0.64) | ALDH1A1HTTSMN1; SMN2KDM4EGAA | |
| SCHEMBL23229951 | 0.81 | PRMT6 (0.59) | ALDH1A1HTTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL13969804 | 0.80 | KDM4E (0.48) | ALDH1A1HTR2ASLC6A4KCNH2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720841-B1 | QUINAZOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | REXAHN PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-8404698-B2 | Quinazoline derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20090030021-A1 | Quinazoline Derivatives and Therapeutic Use Thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-7388014-B2 | Quinazoline derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030021-A1 | Quinazoline Derivatives and Therapeutic Use Thereof | ABL1, NQO2, NRAS | ALDH1A1 2085/4885HTR2A 3196/4885SLC6A4 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.